Press Release: Abacus dx Announces Partnership with Response Biomedical
Abacus dx Announces Commercial Partnership with Response Biomedical in Australia & New Zealand’s Clinical Market Sector
Brisbane, 6th November 2024
Abacus dx Announces Commercial Partnership with Response Biomedical in Australia & New Zealand’s Clinical Market Sector
Brisbane, 6th November 2024
HistoCyte tissue controls are a testament to precision and reliability in the diagnosis of breast cancer.
Discover the Invivoscribe control portfolio
Invivoscribe offers an extensive range of General Purpose Reagents (GPRs) and Research Use Only (RUO) controls.
WHEN TIME MATTERS. THINK BIOCARTIS IDYLLA*. YOUR BIOMARKER TEST RESULTS WITHIN 3 HOURS.
The Idylla™ solution is a revolutionary, fully automated, real-time PCR based molecular testing system designed to offer results in a minimum amount of time.
Early and rapid confirmation of dengue infections strengthens disease surveillance programs and is critical to the success of vector control. Rapid diagnostics tests (RDTs), like the SD Biosensor Dengue Virus Test Kits*, are increasingly used to confirm recent dengue infections due to their ease of use and short turnaround time for results.
Thermo Fisher EliA testing for antiphospholipid syndrome (APS) in relation to the new 2023 APS classification criteria.
One of the essential antibodies used in the panel for differential detection of cervical dysplasia is p16INK4A.
ARID1A is expressed in most normal tissue, and mutations occur in tumours resulting in a loss of expression. ARID1A mutations have been particularly relevant in GI and gynaecological malignancies.